GENE THERAPY IN PRIMATES
GENE THERAPY IN PRIMATES
批准号:
6299330
负责人:
MARK H. TUSZYNSKI
金额:
$18.43万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-03-15 至 2001-02-28
关键词:
Adenoviridae Alzheimer's disease Macaca mulatta acetylcholine aging behavior test cell transplantation choline acetyltransferase disease /disorder model gene targeting gene therapy magnetic resonance imaging nervous system regeneration nervous system transplantation neural degeneration neurons neurotransmitters neurotrophic factors nonhuman therapy evaluation northern blottings positron emission tomography stereotaxic techniques transfection /expression vector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Gene therapy may benefit human neurological disorders such as
Alzheimer~s disease (AD). Grafting cells to the brain that are
genetically modified to produce neurotrophic factors,
neurotransmitters or other therapeutic agents can achieve specific
intraparenchymal drug delivery in a chronic and well-tolerated
manner. In AD, gene therapy could provide a means for
delivering neurotrophic factors such as NGF to degenerating
neurons in the cholinergic basal forebrain and other regions, or
for augmenting neurotransmitter function in the cortex,
hippocampus, and other regions. Gene therapy could also
ultimately provide a means of manipulating the expression of
various genes involved in generating AD pathology. In the first
five-year period of this grant, optimal parameters for transducing
primary primate cells to produce neurotrophic factors and
neurotransmitters in vitro have been developed. Optimal
conditions for grafting genetically modified cells to the brain have
been established. When grafted to the cholinergic basal forebrain,
NGF-producing cells express NGF protein and prevent cholinergic
neuronal degeneration for at least 8 months. New models of
spontaneous age-related cholinergic neuronal degeneration have
also been characterized. The next five-year period of this primate
project will determine 1) whether NGF gene therapy will prevent
lesion-induced and spontaneous age-related declines in basal
forebrain cholinergic neuronal morphology and behavioral function
for prolonged periods of up to two years, 2) if neurotransmitter
replacement by gene therapy will ameliorate lesion-induced and
spontaneous age-related declines in cholinergic biochemistry and
behavioral function, as recently shown in rats, and 3) if the in
vivo efficacy and safety of gene therapy for future clinical trials in
AD can be enhanced by serial MRI and PET imaging, use of
regulatable promoters for controlling in vivo gene expression, and
direct in vivo genetic modification of primary nervous system cells
such as neurons and glia by adenovirus, adeno-associated virus,
and HIV vectors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing human neural progenitor cells (hNPCs) to FDA IND approval
-
批准号:10642228
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The Primate Corticospinal Connectome and Transcriptome - Supplement
-
批准号:10876189
-
项目类别:
-
资助金额:$14.9万
-
财政年份:2023
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
-
批准号:10663796
-
项目类别:
-
资助金额:$112.85万
-
财政年份:2021
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
-
批准号:10185291
-
项目类别:
-
资助金额:$120.15万
-
财政年份:2021
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
-
批准号:10402369
-
项目类别:
-
资助金额:$114.19万
-
财政年份:2021
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
ShEEP request for a Zeiss LSM 880 with Airyscan confocal system
-
批准号:9573958
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The Primate Corticospinal Connectome and Transcriptome
-
批准号:10386916
-
项目类别:
-
资助金额:$63.63万
-
财政年份:2017
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The Primate Corticospinal Connectome and Transcriptome
-
批准号:10211059
-
项目类别:
-
资助金额:$66.34万
-
财政年份:2017
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The Primate Corticospinal Connectome and Transcriptome
-
批准号:10650134
-
项目类别:
-
资助金额:$63.09万
-
财政年份:2017
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
RR&D Gordon Mansfield Spinal Cord Injury Consortium
-
批准号:10538563
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
RR&D Gordon Mansfield Spinal Cord Injury Consortium
-
批准号:9822285
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
RR&D Gordon Mansfield Spinal Cord Injury Consortium
-
批准号:10322642
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The VA Gordon Mansfield SCI Consortium
-
批准号:10267465
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The VA Gordon Mansfield SCI Consortium
-
批准号:9468259
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
The VA Gordon Mansfield SCI Consortium
-
批准号:8804160
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Translational Program of BDNF Gene Delivery in Alzheimer's Disease
-
批准号:8927970
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2014
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Translational Program of BDNF Gene Delivery in Alzheimer's Disease
-
批准号:8868875
-
项目类别:
-
资助金额:$86.19万
-
财政年份:2014
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Translational Program of BDNF Gene Delivery in Alzheimer's Disease
-
批准号:8579707
-
项目类别:
-
资助金额:$119.42万
-
财政年份:2014
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Translational Program of BDNF Gene Delivery in Alzheimer's Disease
-
批准号:9318419
-
项目类别:
-
资助金额:$59.56万
-
财政年份:2014
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
A Translational Program of BDNF Gene Delivery in Alzheimer's Disease
-
批准号:9114022
-
项目类别:
-
资助金额:$92.55万
-
财政年份:2014
-
负责人:MARK H. TUSZYNSKI
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: